Fig. 3From: Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationEffect of baseline VA on injection interval length at Month 12. CI, confidence interval; Q, quartile; VA, visual acuityBack to article page